Total: $503.35M | ||||
Company |
Type Of |
Number Of |
Amount |
Investors; Placement Agents; Details (Date)@ |
|
|
||||
Abcam plc |
Private placement of stock |
6S |
£10 (US$17.4) |
The shares were sold at 167 pence each; totals do not include £5.25 raised by selling shareholders; the company also gained a listing on the AIM; Numis Securities was placement agent (11/3) |
| ||||
Angel |
Private placement of stock |
136.4S |
£1.5 (US$2.6) |
The company gained admission to the Alternative Investment Market in conjunction with the financing (11/11) |
|
||||
AVI |
Private |
6.9S |
$22.6 |
The shares were sold from a shelf registration at $3.26 each in a direct placement; Rodman & Renshaw LLC was placement agent (11/14) |
|
||||
BioInvent |
Rights |
17.685S |
SEK160 (US$19.5) |
Shares were sold at SEK9 per share in the deal in which existing shareholders got preference rights (11/2) |
|
||||
Carrington |
Private placement of notes and warrants |
N/A and 5W |
$5 |
The $5M in 6% notes are due in 2006; half the four-year warrants are exercisable at $5 per share and half at $10 per share (11/21) |
|
||||
Cell |
Private placement of convertible notes |
N/A |
$82 |
The 6.75% senior notes due in 2010 are convertible into common stock at an initial price of $2.629 per share (11/1) |
|
||||
Delcath |
Private placement of stock and warrants |
0.753S and 0.188W |
$2.5 |
H.C. Wainwright & Co. Inc. was placement agent for the deal, terms of which were not disclosed (11/28) |
|
||||
Evolutec |
Private placement of stock |
6.25S |
£10 (US$17.3) |
The financing was fully underwritten by Robert W. Baird (11/11) |
|
||||
GammaCan |
Private placement of securities |
ND |
$0.5 |
Sal. Oppenheim Jr. & Cie. Ltd. invested in the deal and has an option to invest an additional $2M; terms were not disclosed (11/15) |
|
||||
Helix |
Private placement of stock and warrants |
3.156S and 3.156W |
C$5.52 (US$4.65) |
The private placement was completed in Europe; the warrants are exercisable at C$2.45 until March 31, 2008 (11/7) |
|
||||
Javelin |
Private placement of stock and warrants |
14.22S and 0.711W |
$32 |
The financing was led by NGN Capital and funds affiliated with Wexford Capital LLC; the five-year warrants are exercisable at $2.25 per share; Rodman & Renshaw LLC and Riverbank Capital Securities Inc. were placement agents (11/3) |
|
||||
Karo Bio AB |
Rights issue |
46.4S |
SEK278.7 (US$33.8) |
The rights issue was 98% subscribed with preferential right for the shareholders (11/14) |
|
||||
Novavax Inc. |
Private placement of stock |
4.186S |
$18 |
The stock was sold from a shelf registration at $4.30 per share; Rodman & Renshaw LLC was placement agent (11/2) |
|
||||
Nymox |
Private placement of stock |
ND |
$13 |
The stock was priced at a 3% discount to the market price; further terms were not disclosed (11/2) |
|
||||
Oragenics Inc. |
Private placement of stock and warrants |
3S and 3W |
$1.2 |
The shares were sold at $0.40 each and the two- year warrants are exercisable at $0.60 per share (11/21) |
|
||||
Oxford |
Private placement and open offer |
120.3S |
£30.1 (US$51.7) |
The deal was fully underwritten by Evolution Securities; shares were sold at 25 pence each; Sigma-Aldrich Corp. invested £2.9M; NM Rothschild & Sons was financial adviser in the deal (11/16) |
|
||||
Peregrine |
Private placement of stock |
8S |
$6.7 |
The shares were sold to Double U Master Fund LP (11/23) |
|
||||
Pharmaxis |
Private placement of stock |
19.9S |
A$43.8 (US$32) |
The placement was completed with Australian and other investors concurrently with a public offering in the U.S., which raised another $31.4M (11/8) |
|
||||
Pharmexa A/S |
Private placement of stock |
3.4S |
DKK72.9 (US$11.5) |
The shares were sold at DKK21.45 each, following a deal to acquire certain assets from IDM Pharma Inc.; ING was placement agent (11/24) |
|
||||
Phoqus Group |
Private placement of stock |
7.14S |
£10 (US$17.5) |
Phoqus gained listing on the Alternative Investment Market through the sale of shares at 140 pence each; Code Securities underwrote the deal (11/3) |
|
||||
Sangamo |
Private placement of stock |
5.08S |
$19.5 |
Institutional investors and Dow AgroSciences LLC purchased about 5.08M shares at $3.85 per share; JMP Securities and Piper Jaffray & Co. were lead placement agents; Leerink Swann & Co. was co-placement agent (11/11) |
|
||||
SemBioSys |
Debt financing |
N/A |
C$2.5 (US$2.1) |
The long-term debt financing was secured from Oxford Finance Corp. (11/21) |
|
||||
SIGA |
Private placement of stock and warrants |
2S and 1W |
$2 |
The shares were sold for $1 each, and the seven- year warrants are exercisable at 110% of the Nov. 2 closing price; investors can purchase another $2M in stock at $1.10 per share; The Shemano Group was placement agent (11/3) |
|
||||
Solexa Inc. |
Private placement of stock and warrants |
10S and 3.5W |
$65 |
The shares were sold at $6.50 each, and the warrants are exercisable at $7.50 per share; about 60% of the deal will close after shareholder approval (11/21) |
|
||||
Starpharma |
Private placement of stock and share purchase plan |
29.4S |
A$15 (US$11) |
The deal included an A$12M institutional placement and an A$3M underwritten share purchase plan; shares were priced at A$0.51 in both deals; Patersons Securities was lead agent in the placement and underwriter of the SPP (11/14) |
|
||||
Stressgen |
Private placement of stock and warrants |
7.645U |
C$2.68 (US$2.3) |
Each unit conists of one share and one-third of a warrant; each full warrant is exercisable for two years to purchase one share at C$0.50 each; Canaccord Capital Corp. was placement agent (11/1) |
|
||||
Viventia |
Warrants exercise |
ND |
C$12 (US$10) |
The Dan Group exercised C$12M in warrants; then the group was repaid C$12M owed in promissory notes; the Dan Group now owns more than 90% of the company and plans to acquire the rest (11/14) |
|
|
||||
Notes: | ||||
This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt. | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
N/A = Not applicable; ND = Not disclosed. | ||||
AIM = Alternative Investment Market; AMEX = American Stock Exchange; ASX = American Stock Exchange; CSE = Copenhagen Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; TSE = Toronto Stock Exchange. | ||||
To read more on related topics, click on one of the words below.